BeOne Medicines (ONC) Enterprise Value (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Enterprise Value data on file, last reported at -$4.8 billion in Q1 2026.

• On a quarterly basis, Enterprise Value fell 90.42% year-over-year to -$4.8 billion in Q1 2026; TTM through Mar 2026 was -$4.8 billion, a 90.42% decrease from a year earlier, with the FY2025 full-year figure at -$4.5 billion, down 73.08% from the prior year.
• Enterprise Value for Q1 2026 stood at -$4.8 billion, down from -$4.5 billion in the prior quarter.
• Over the last five years, Enterprise Value for ONC reached as high as -$872.2 million in Q3 2022 and fell as low as -$5.7 billion in Q2 2022.
• Historically, Enterprise Value has averaged -$3.3 billion across 5 years, with a median of -$3.2 billion in 2023.
• Across the five-year window, Enterprise Value soared 77.73% in 2022 and tumbled 263.95% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$4.5 billion in 2022, then advanced by 30.0% to -$3.2 billion in 2023, then grew by 17.23% to -$2.6 billion in 2024, then tumbled by 73.08% to -$4.5 billion in 2025, then retreated by 5.37% to -$4.8 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$4.8 billion in Q1 2026, -$4.5 billion in Q4 2025, and -$4.0 billion in Q3 2025.